id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0556-0026,FDA,FDA-2021-N-0556,Development of Non-Opioid Analgesics for Acute Pain; Guidance for Industry; Draft Guidance,Other,Guidance,2026-05-13T04:00:00Z,2026,5,2026-05-13T04:00:00Z,,2026-05-13T15:20:57Z,,1,0,09000064b92d0c73
FDA-2021-N-0556-0001,FDA,FDA-2021-N-0556,Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-02-10T05:00:00Z,2022,2,2022-02-10T05:00:00Z,2022-04-12T03:59:59Z,2022-04-13T01:00:29Z,2022-02858,0,0,0900006484f680e9
FDA-2021-N-0556-0002,FDA,FDA-2021-N-0556,Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry; Availability,Other,Guidance,2022-02-10T05:00:00Z,2022,2,2022-02-10T05:00:00Z,2022-04-12T03:59:59Z,2024-11-12T23:36:42Z,,1,0,0900006484f6937f